华瑞同康生物技术（深圳）有限公司

华瑞同康 specializes in the development and commercialization of innovative diagnostic solutions for early cancer screening, using its proprietary TK1-based technology. Its core product line, “体可问®️TK1”, has achieved broad adoption across China’s healthcare system, with inclusion in basic medical insurance directories of most provinces. The company’s products are used for health checkup screening, tumor efficacy evaluation, prognosis assessment, and recurrence/metastasis risk warning throughout the tumor management cycle[1][2]. Their technologies have received multiple awards and certifications including NMPA registration and CE marking.